Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Activist Alex Denner’s Sarissa Capital Bets on Ariad Pharmaceuticals Inc (ARIA), Quest Diagnostics Inc (DGX) & Others

Alex Denner’s Sarissa Capital disclosed its holdings in its latest and first 13F filings. The hedge fund has invested $267.02 million in equity portfolio and is focusing mainly on the Healthcare sector.

The hedge fund holds more than 30% of its portfolio value in Ariad Pharmaceuticals Inc (NASDAQ:ARIA). The fund has 12 million shares, worth $81.84 million. Ariad is facing difficulties since the FDA asked it to withdraw its only drug Iclusig from the market in October, 2013. It was allowed to continue the sales but to a very small group of patients. Sarissa holds a 6.2 % stake in the company and has asked to nominate several directors to the company’s board.

Alex Denner Sarissa Capital

The second largest holding is in Quest Diagnostics Inc (NYSE:DGX). The hedge fund holds 14% of its equity portfolio in the company, owning 700,000 shares worth $37.48 million. Quest is expected to be hit by the provisions of the Affordable Care Act. It has already lost 3% of revenues in 2013 from reimbursement changes.

The third largest holding is in Idenix Pharmaceuticals Inc (NASDAQ:IDIX). The fund has invested $30.20 million in 5.05 million shares of the company. Baupost Group, managed by Seth Klarman, also holds a substantial holding in Idenix. The fund owns 53.33 million shares equaling 35.38% of the common stock. Baupost has been granted observer rights with respect to meetings of the board of directors of the company and the committees of the company’s board of directors.

With a $23.37 million stake, which amasses 2.54 million shares, Vivus Inc (NASDAQ:VVUS) is the fourth largest holding of Sarissa. Sarissa partnered with First Manhattan to wage a proxy battle at Vivus and succeeded in replacing the company’s Chief Executive besides placing six nominees on the company’s board.

The fund has also invested $20.02 million in 400,000 shares of Merck & Co Inc (NYSE:MRK). Merck is planning to sell its portfolio of consumer brands. It has already screened the preliminary offers and is waiting for the final bids. The sale is expected to yield $10 billion to the company.

Disclosure: none

Recommended Reading:

Renaissance Technologies Loves These Stocks: McDonald’s Corporation (MCD), Novo Nordisk A/S (ADR) (NVO) & Others

Kyle Bass and Hayman Capital’s Top Stock Picks: General Motors Company (GM), Vodafone Group Plc (ADR) (VOD) & Others

Valiant Capital’s Top Picks From The Latest 13: Apple Inc. (AAPL), Liberty Global plc (LBTYA) & More

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!